Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > draw no conclusions

<< Previous

Bullboard Posts

Next >>

Comment by Gessurongon Apr 10, 2024 9:56am

179 Views

Post# 35980974

RE:draw no conclusions

MrMugsy wrote: The price will move up and down - doesn't matter.
The price doesn't represent anything right now because we don't have a market.
A few thousand shares traded daily, makes not a market.
Isn't that the old saying? Hahaha.

So ...

If you're here and you are holding shares ... it's because you believe in the story or you desperately want to believe in the story.

If you only beleive in the drug and not the team - that's foolish - because that means you're banking on an acquisition.

I wouldn't do that !

I would bet on partnerships - lots of them - with no acquisition. If we get an acquisition that's great!!! But don't expect one. Expecting an acquisition will make for a very bitter next few years.

: )

2023 is all about OTENA - in my opinion. Even if we don't see it - it's about figuring out acute and chronic.

2023 was about setting up IBD for future value - but - don't believe it's about IBD ... the story is about autoimmune opportunities - lots of them.

I also think 2023 is about Ketorolac. Maybe not, but if our future consists of opportunities with tumors/cancer then Ketorolac is likely a smart move.

2023 is also about respiratory ... as I was recently shown a study related to our 344 and Wallace's participation in that study. This likely builds off of Buret's patent application for 344/Indomethacin back a year or so ago.

Remember - nothing is as it seems. Nothing is ever as it seems. But, patience and trust is required if you're making these kinds of bets.

The company is also patiently building the pathway of opportunity - again - in my opinion.

The funnel is as important to the future as is OTENA. Many will argue that it's all about OTENA - but - if OTENA is the key to the lock, the funnel is what stands behind the door once the door is opened.

Don't look at the prize for Big Pharma as being OTENA - look at what the company represents in the future as the prize. Until then, look at OTENA as being the partnership-maker and the funnel as what seals the big dollar deal down the road. It's a pharma risk - every investor should know that.

Fiinally - don't fret the price movements. P2 (before and after) is going to scare you. The fear is real. Waiting is going to suck. Not knowing if there are problems is going to haunt you. You will be watching the share price for clues but it won't be much help.

Panic will make you sell and excitement on the markets will make you buy it back - hahaha.
It's true.
You have to think about all that - years before you buy into a baby pharma.

That's what makes this the coolest game on the planet - good luck.